Vasopressin receptor antagonists: The vaptans;Antagonistas del receptor de vasopresina: Los vaptanes

Endocrinologia y Nutricion

Volumn 57, Issue SUPPL. 2, 2010, Pages 41-52

  Villabona, Carles ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Antagonist receptor; AVP receptor; Hyponatremia; Vasopressin

Indexed keywords

AQUAPORIN 2; CALCIUM ION; CORTICOTROPIN; ELECTROLYTE; INOSITOL PHOSPHATE; LIXIVAPTAN; MOZAVAPTAN; SATAVAPTAN; TOLVAPTAN; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V1B RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ADENOHYPOPHYSIS; ANTIDIURESIS; ARTICLE; BLOOD VESSEL; HEART FAILURE; HEART MUSCLE; HORMONE RELEASE; HUMAN; HYPONATREMIA; HYPOPHYSIS; KIDNEY COLLECTING TUBULE; LIVER CIRRHOSIS; SIGNAL TRANSDUCTION;

ADULT; AQUAPORIN 2; BENZAMIDES; BENZAZEPINES; CALCIUM SIGNALING; CLINICAL TRIALS AS TOPIC; CYCLIC AMP; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HEART FAILURE; HUMANS; HYPONATREMIA; INAPPROPRIATE ADH SYNDROME; KIDNEY TUBULES, COLLECTING; LIVER CIRRHOSIS; MORPHOLINES; MULTICENTER STUDIES AS TOPIC; NEOPLASMS; PITUITARY GLAND, ANTERIOR; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, VASOPRESSIN; SECOND MESSENGER SYSTEMS; SPIRO COMPOUNDS; VASOPRESSINS;

EID: 78649824668     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/S1575-0922(10)70021-8     Document Type: Article

References (103)

1. Robertson G.L., Mahr E.A., Athar S., Sinha T. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest 1973, 52:2340-2352.
2. Gross P., Pehrisch H., Rascher W., Schöming A., Hackenthal E., Ritz E. Pathogenesis of clinical hyponatremia. Observations of vasopressin and fluid intake in 1 000 hyponatremic medical patients. Eur J Clin Invest 1987, 17:123-129.
3. Leaf A., Mamby A.R. An antidiuretic mechanism not regulated by extracelullar fluid tonicity. J Clin Invest 1952, 31:60-71.
4. Schrier R.W., Berl T. Nonosmolar factors affecting renal water excretion. N Engl J Med 1975, 292:81-87. 141-4.
5. Schrier R.W. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy. N Engl J Med 1988, 319:1065-1072.
6. Boykin J., De Torrente A., Robertson G.L., Erickson A., Schrier R.W. Persistent plasma vasopressin levels in the hypoosmolar state associated with mineralcorticod deficiency. Miner Elecrolyte Metab 1979, 2:310-315.
7. Bichet D., Szatawicz V., Chaimovitz C., Schrier R.W. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med 1982, 96:413-417.
8. Goldsmith S.R., Francis G.S., Cowley A.W. Arginine vasopressin and the renal response to water loading in congestive heart failure. Am J Cardiol 1986, 58:295-299.
9. Usberti M., Federico S., Meccariello S., Cianciaruso B., Balleta M., Pecovaro C., et al. Role of plasma vasopressin in the impairment of water excretion in nephrotic syndrome. Kidney Int 1984, 25:422-429.
10. Zerbe R., Stropes L., Robertson G. Vasopressin function in the syndrome of inappropiate antidiuresis. Ann Rev Med 1980, 31:315-327.
11. Manning M., Sawyer W.H. Development of selective agonists and antagonists of vasopresin and oxytocin. Vasopressin 1985, 131-144. Raven Press, New York. R.W. Schrier (Ed.).
12. Manning M., Sawyer W.H. Antagonists of vasopressin and oxytocin:current status and future perspectives. Vasopresin 1991, 297-309. John Libbey Eurotext, Paris. S. Jard, R. Jamison (Eds.).
13. Yamamura Y., Ogawa H., Yamashita H., Chihara T., Miyamoto H., Nakamura S., et al. Characterization of a novel aquaretic agent OPC-31260 as an orally efective nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 1992, 105:787-791.
14. Ohnishi A., Orita Y., Okahara R., Fujihara R., Inove T., Yamamura Y. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J Clin Invest 1993, 92:2653-2659.
15. Verbalis J.G., Goldsmith S.R., Greenberg A., Schrier R.W., Sterns R.H. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007, 120:S1-S21.
16. Serradeil-Le Gal G., Wagnon J., Garcia G., Lacour C., Guinaudou P., Christophe B., et al. Biochemical and pharmacological properties of SR 49059, a new potent non-peptide antagonist of rat and human vasopressin V1 receptors. J Clin Invest 1993, 92:224-231.
17. Serradeil-LeGal C., Lacour C., Valette G., Garcia G., Foulon L., Galindo G., et al. Characterisation of SR 121 463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest 1996, 98:2729-2738.
18. Matsuhisa A., Tanaka A., Kikuchi K., Shimada Y., Yatsu T., Yanagisa W.A. Non peptide arginine vasopressin antagonists for both V1a and V2-receptors: synthesis and pharmacological properties of 2-phenyl4-(2,3,4,5-tetrahydro-1H-1-benzazepin-1-y)-Carbonyl) benzanilide derivations. Chem Pharm Bull 1997, 45:1870-1874.
19. Tahara A., Tomura Y., Wada K., Kusayama T., Tsukuda J., Takanashi M., et al. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo. J Phamarcol Exp Ther 1997, 282:301-308.
20. Serradeil-Le Gal C., Wagnon J., Simiand J., Griebel G., Lacour C., Guillon G., et al. Characterization of SSR149415, a selective and orally-active vasopressin V1b receptor antagonist. J Pharmacol Exp Ther 2002, 300:1122-1130.
21. Bolignano D., Coppolino G., Criseo M., Campo S., Romeo A., Buemi M. Aquaretic agents: What's beyond the treatment of hyponatremia?. Curr Pharmaceut Desig 2007, 13:865-871.
22. Bichet D.G. Vasopressin receptors in health and disease. Kidney Int 1996, 49:1706-1711.
23. Holmes C.L., Landry D.W., Granton J.T. Science review: vasopressin and the cardiovascular system part 1-receptor physiology. Crit Care 2003, 7:427-434.
24. Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2-receptor-mediated effects. Cardiosvasc Res 2001, 51:372-390.
25. Knepper M.A., Wade J.D., Terris J., Ecelbarger A., Marples D., Mandon B., et al. Renal aquaporins. Kidney Int 1996, 49:1712-1717.
26. Nielsen S., Marples D., Frokiaer J., Knepper M., Agre P. The aquaporin family of water channels in kidney: an update on physiology and pathophysiology of aquaporin-2. Kidney Int 1996, 49:1718-1723.
27. Nielsen S., Kwon T., Christensen M., Promeneur D., Frokiaer J., Marples D. Physiology and pahtophysiology of renal aquaporins. J Am Soc Nephrol 1999, 10:647-663.
28. Nielsen S., Frokiaer J., Marples D., Kwon T., Agre P., Knepper M.A. Aquaporins in the kidney: from molecules to medicine. Phsiol Rev 2002, 82:205-244.
29. Buemi M., Corica F., Di Pasquale G., Aloisi C., Sofi M., Latassa G., et al. Water immersion increases urinary excretion of aquaporin-2 in healthy humans. Nephron 2000, 85:20-26.
30. Pool PE. The clinical significance of neurohormonal activation. Clin Ther 1997, 19(Suppl A):53-73.
31. Thibonnier M. Vasopressin receptor antagonists in heart failure. Curr Opin Pharmacol 2003, 3:683-687.
32. Lee C.R., Watkins M.L., Patterson J.H., Gattis W., O' Connor C.M., Gheorghiade M., et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J 2003, 146:9-18.
33. Goldsmith S.R. The role of vasopressin in congestive heart failure. Clev Clin J Med 2006, 73(Suppl 3):S19-S23.
34. Verbalis J.G. Vasopressin V2 receptor antagonists. J Mol Endocrinol 2002, 29:1-9.
35. Greenberg A., Verbalis J.G. Vasopressin receptor antagonists. Kidney Int 2006, 69:2124-2130.
36. Palm C., Pistroch F., Herbrig K., Gross P. Vasopressin as aquaretic agents for the treatment of hyponatremia. Am J Med 2006, 119:S87-S92.
37. Quittnat F., Gross P. Vaptans and the treatment of water-retaining disorders. Semin Nephrol 2006, 26:234-243.
38. Macion-Dazard R., Callahan N., Xu Z., Wu N., Thibonnier M., Sholam M. Mapping the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor. J Pharmacol Exp Ther 2006, 316:564-571.
39. Ali F., Guglin M., Vaitkevicius P., Ghali J.K. Therapeutical potential of vasopressin receptor antagonists. Drugs 2007, 67:847-858.
40. Decaux G., Soupart A., Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 2008, 371:1624-1632.
41. Chan P.S., Coupet J., Park H.C., Lai F., Hartupee D., Cervoni P., et al. VPA-985 a nonpeptide oraly active and selective vasopressin V2 receptor antagonist. Vasopressin and oxytocin; molecular, cellular and clinical advances 1998, 439-443. Raven Press, New York. H.H. Zingg, C.W. Bourque, D.G. Bichet (Eds.).
42. Wong F., Blei A.T., Biendis L.M., Thuluvath P.J. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003, 37:182-191.
43. Gerbes A.L., Gulberg V., Gines P., Decaux G., Gross P., Gandjini H., et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003, 124:933-939.
44. Abraham W.T., Shamshirsaz A.A., McFann K., Oren R.M., Schrier R.W. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association Functional Class II and III Chronic Heart Failure Patients. J Am Coll Card 2006, 47:1615-1621.
45. Soupart A., Gross P., Legros J.J., Alföldi S., Annane S., Heshmati H., et al. Successful long-term treatment of hyponatremia in syndrome of inappropiate antidiuretic hormone secretion with satavaptan (SR 121 463 B), an orally active non peptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol 2006, 1:1154-1160.
46. Nat Clin Pract 2007, 3:122. Long-term efficacy of satavaptan in patients with SIADH-related hyponatremia (editorial).
47. Yamamura Y., Nakamura S., Itoh S., Hirano T., Onogawa T., Yamashita T., et al. OPC 41061, a highly potent human vasopressin V2 receptor antagonist: pharmacological profile and aquaretic effect by single and multple oral dosing in rats. J Pharmacol Exp Ther 1998, 287:860-867.
48. Verbalis J.G. AVP receptor antagonists as aquaretics: review and assessment of clinical data. Clev Clin J Med 2006, 73:S24-S33.
49. Udelson J.E., Orlalindi C., O'Brien T., et al. Vasopressin receptor blockade in patients with congestive heart failure: results from a placebo-controlled, randomized study comparing the effects of tolvaptan, furosemide, and their combination (abstract). J Am Coll Cardiol 2002, 39:156A.
50. Uldeson J.E. The METEOR Trial Investigators Multicenter randomized double-blind, placebo-controlled, efficacy study on the effects of oral tolvaptan on LV dilatation and function in patients with HF and LV systolic dysfunction. The 9th Annual Scientfic Meeting of Heart Failure Society of America 2005.
51. Udelson J.E., McGrew F.A., Flores E., Ibrahim H., Katz S., Koshkarian G., et al. Multicenter, randomized, double-blind, placebo study on the effect of oral tolvaptan on left ventricular dilation and function inpatient with heat failure and systolic dysfunction. J Am Coll Cardiol 2007, 49:2151-2159.
52. Schrier R.W., Gross P., Gheorgiade M., et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006, 355:2099-2112.
53. Weise W.L., Rimmer J.M., Hood V.L. Tolvaptan for hyponatremia (letter). N Engl J Med 2007, 356:961.
54. Hays R.M. Vasopressin antagonists-Progress and Promise. N Engl J Med 2006, 355:2146-2148.
55. Adler S.M., Verbalis J.G., Ouyang J., et al. Management of SIADH with tolvaptan: a subanalysis from the SALT trials. American Association of Clinical Endocrinologists Conference 2007, Abstract 368.
56. Decaux G. Long-term treatment of patients with inappropiate secretion of antidiuretic hormone by the vasopressin antagonist conivaptan, urea, or furosemide. Am J Med 2001, 110:582-584.
57. Ghali J.K., Koren M.J., Taylor J.R., Brooks-Asplund E., Fan K., Long W.A., et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assesssed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 2006, 91:2145-2152.
58. Udelson J.E., Smith W.B., Hendrix G.H., Painchaud C.A., Ghazzi M., Thomas I., et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin recetor antagonist, in patients with advanced heart failure. Circulation 2001, 104:2417-2423.
59. Zeltser D., Rosanasky S., Van Rensburg H., Verbalis J.G., Smith N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol 2007, 27:447-457.
60. Verbalis J.G., Zeltser D., Smith N., Barve A., Andoh M. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolemic hyponatraemia: subgroup analysis of a randomized, controlled study. Clin Endocrinol (Oxf) 2008, 69:159-168.
61. Murphy T., Dhar R., Diringer M. Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit. Neurocrit Care 2009, Epub ahead of print.
62. Wright W.L., Asbury W.H., Gilmore J.L., Samuels O.B. Conivaptan for hyponatremia in the neurocritical care unit. Neurocrit Care 2008, Epub ahead of print.
63. Fields J.D., Bhardwaj A. Non-peptide arginine-vasopressin antagonists (vaptans) for the treatment of hyponatremia in neurocritical care: a new alternative?. Neurocrit Care 2009, 1:1-4.
64. Hayoz D., Bizzini G., Noel B., Depairon M., Burnier C., Faveau A., et al. Effect of SR49059, a V1a vasopressin receptor antagonist in Raynaud's phenomenon. Rheumatology 2000, 39:1132-1138.
65. Steinwall M., Bossmar T., Brouard R., Laudanski T., Olofsson P., Urban R., et al. The effect of Relcovaptan (SR 49059), an orally active vasopressin V1a-receptor anatagonist on uterine contraction in preterm labor. Gynecol Endocrinol 2005, 20:104-109.
66. Brouard R., Bossmar T., Fournie-Lloret D., Chassard D., Akerlund M. Effect of SR 49059, and orally active V1a vasopressin receptor antagonist in the prevention of dysmenorrhoea. Br J Obstet Gynaecol 1999, 106:1047-1053.
67. Daidoh H., Morita H., Hanafusa J., Mune T., Murase H., Sato M., et al. In vivo and in vitro effects of AVP and V1a receptor antagonist on Cushing's syndrome due to ACTH-independent bilateral macronodular adrenocortical hyperplasia. Clin Endocrinol (Oxf) 1998, 49:403-409.
68. Sonino N., Boscaro M., Fallo F. Pharmacologic management of Cushing syndrome: new target for therapy. Treat Endocrinol 2005, 4:87-94.
69. Griebel G., Simiand J., Serradeil-Le Gal C., Wagnon J., Pascal M., Scatton B., et al. Anxiolytic-and-antidepressant-like effects of the non-peptide vasopressin V1b-receptor antagonist. SSR149415, suggest and innovatrice approach for the treatment of stress-related disorders. PNAS 2002, 99:6370-6375.
70. Gross P. Treatment of hyponatremia. Inter Med 2008, 47:885-891.
71. Decaux G., Soupart A. Treatment of symptomatic hyponatremia. Am J Med Sci 2003, 326:25-30.
72. Sterns R.H., Nigwekar S.U., Hix J.K. The treatment of hyponatremia. Semin Nephrol 2009, 29:282-299.
73. Lien Y.H., Shapiro J.I. Hyponatremia: clinical diagnosis and management. Am J Med 2007, 120:653-658.
74. Goh K.P. Management of hyponatremia. Am Fam Phys 2004, 69:2387-2394.
75. Abbott R., Silber E., Felber J., Ekpo E. Osmotic demyelination syndrome. Br Med J 2005, 331:829-830.
76. Adrogué H.J. Consequences of inadequate management of hyponatremia. Am J Nephrol 2005, 25:240-249.
77. Furst H., Hallows K., Post J., Chen S., Kotzker W., Goldfarb S., et al. The urine/plasma electrolyte ratio: a predictive guide to water restricion. Am J Med Sci 2000, 319:240-244.
78. White M.G., Fetner C.D. Treatment of the syndrome of inappropiate secretion of antiduretic hormone with lithium carbonate. N Engl J Med 1975, 292:81-87.
79. Juurlink D.N., Mamdani M.M., Kopp A., Rochon P.A., Shulman K.I., Redelmeier D.A. Drug-induced lithium toxicity in the elderly: a population-based study. J Am Geriatr Soc 2004, 52:794-798.
80. Forrest J.N., Cox M., Hong C., Morrison G., Bia M., Singer I. Superiority of demeclocycline over lithium in the treatment of chronic syndrome of inappropiate secretion of antidureitc hormone. N Engl J Med 1978, 298:178-179.
81. Decaux G., Brimioulle S., Genette F., Mockel Jl. Treatment of the syndrome of inappropiate secretion of antidureitc hormone by urea. Am J Med 1980, 69:99-106.
82. Decaux G., Brimioulle S., Genette F., Mockel J. Treatment of the syndrome of inappropiate secretion of antiduretic hormone by urea. Am J Med 1981, 83:1081-1083.
83. Hantman D., Rossier B., Zohlman R., Schrier R. Rapid correction of hyponatremia in the syndrome of inappropiate secretion of antiduretic hormone. An alternative treatment to hypertonic saline. Ann Intern Ned 1973, 78:870-876.
84. Lehrich R.W., Greenberg A. When is it appropiate to use vasopressin receptor antagonists?. J Am Soc Nephrol 2008, 19:1054-1058.
85. Rai A., Ehaley-Connell A., McFarla N.E., Sowers J.R. Hyponatremia, arginine vasopressin dysregulation, and vasopressin receptor antagonism. Am J Nephrol 2006, 26:579-589.
86. Yeates K.E., Moreton A.R. Vasopressin antagonists: role in the management of hyponatremia. Am J Nephrol 2006, 26:348-355.
87. Hoorn E.J., Zietse R. Hyponatremia revisited: translating physiology to practice. Nephron Physiol 2008, 108:46-59.
88. Jennings D.L., Kalus J.S. Tolvaptan. Formulary 2008, 43:236-249.
89. Ghali J.K., Hamad B., Yasothan U., Kirkpatrick P. Tolvaptan. Nat Rev 2009, 8:611-612.
90. Gross P., Marczewski T., Herbrig K. The vaptans ante portas: a status report. Nephrol Dial Transplant 2009, 24:1371-1373.
91. Feldman B.J., Rosenthal S.M., Vargas G.A., Fenwick R.G., Huang E.A., Matsuda-Abedini M., et al. Nephrogenic syndrome of inappropiate antidiuresis. N Engl J Med 2005, 352:1884-1890.
92. Decaux G., Vandergheynst F., Bouko Y., Parma J., Vassart G., Vilain C. Nephrogenic syndrome of inappropiate antiduresis in adults: high phenotypic variability in men and women from a large pedigree. J Am Soc Nephrol 2007, 18:606-612.
93. Decaux G. The syndrome of inappropiate secretion of antidiuretic hormone (SIADH). Semin Nephrol 2009, 29:239-256.
94. Baylis P.H. The syndrome of inappropiate antidiuretic hormone secretion. Int J Biochem Cell Biol 2003, 35:1495-1499.
95. Ellison D.H., Berl T. The syndrome of inappropiate antidiuresis. N Engl J Med 2007, 356:2064-2072.
96. Halperin M.J., Kamel K.S. A new look at an old problem: therapy of chronic hyponatremia. Nat Clin Pract Nephrol 2007, 3:2-3.
97. Fernández-Varo G., Ros J., Cejudo-Martín P., Cano C., Arroyo V., Rivera F., et al. Effect of the V1a/V2-AVP receptor antagonist. Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascitis. J Hepatol 2003, 38:755-761.
98. Goldsmith S.R. Is there a cardiovascular rationale for the use of combined vasopressin V1a/V2 receptor antagonists?. Am J Med 2006, 119:S93-S96.
99. Goldsmith S.R. Treatment options for hyponatremia in heart failure. Heart Fail Rev 2009, 14:65-73.
100. Wang X., Ward C.J., Harris P.C., Torres V.E. Cyclic nucleotide signaling in plycystic kidney disease. Kidney Int 2009, doi:10.1038/ ki.2009.438.
101. Torres V.E., Harris P.C. Autosomal dominant polycystics kidney disease: the last 3 years. Kidney Int 2009, 76:149-158.
102. Torres V.E. Vasopressin in chronic disease: an elephant in the room?. Kidney Int 2009, 76:925-928.
103. Torres V.E. Vasopressin in polycystic kidney disease. Kidney Int 2005, 68:2405-2418.